PT810880E - Composicoes farmaceuticas e ensaios que utilizam subunidades enzimaticas - Google Patents

Composicoes farmaceuticas e ensaios que utilizam subunidades enzimaticas

Info

Publication number
PT810880E
PT810880E PT96903111T PT96903111T PT810880E PT 810880 E PT810880 E PT 810880E PT 96903111 T PT96903111 T PT 96903111T PT 96903111 T PT96903111 T PT 96903111T PT 810880 E PT810880 E PT 810880E
Authority
PT
Portugal
Prior art keywords
agent
subunities
enzyme
tests
pharmaceutical compositions
Prior art date
Application number
PT96903111T
Other languages
English (en)
Inventor
Richard Eilliam Titball
Francis Joseph-Eclagen Limited
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Publication of PT810880E publication Critical patent/PT810880E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT96903111T 1995-02-22 1996-02-21 Composicoes farmaceuticas e ensaios que utilizam subunidades enzimaticas PT810880E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503486.4A GB9503486D0 (en) 1995-02-22 1995-02-22 Pharmaceuticals and assays using enzyme subunits

Publications (1)

Publication Number Publication Date
PT810880E true PT810880E (pt) 2003-02-28

Family

ID=10770034

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96903111T PT810880E (pt) 1995-02-22 1996-02-21 Composicoes farmaceuticas e ensaios que utilizam subunidades enzimaticas

Country Status (15)

Country Link
US (2) US6472365B1 (pt)
EP (1) EP0810880B1 (pt)
JP (1) JPH11500136A (pt)
KR (1) KR19980702499A (pt)
CN (1) CN1188704C (pt)
AT (1) ATE224204T1 (pt)
AU (1) AU714396B2 (pt)
CA (1) CA2213566A1 (pt)
DE (1) DE69623755T2 (pt)
DK (1) DK0810880T3 (pt)
ES (1) ES2182962T3 (pt)
GB (1) GB9503486D0 (pt)
PT (1) PT810880E (pt)
WO (1) WO1996025952A1 (pt)
ZA (1) ZA961427B (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463090A (en) * 1981-09-30 1984-07-31 Harris Curtis C Cascade amplification enzyme immunoassay
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
GB8528761D0 (en) 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
EP0301333A3 (en) 1987-07-29 1992-07-01 Abbott Laboratories Liposome based homogeneous immunoassay for diagnostic tests
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
JPH04200632A (ja) 1990-11-29 1992-07-21 Toyo Ink Mfg Co Ltd リポソームの破壊方法
JPH0556797A (ja) 1991-08-31 1993-03-09 Toyo Ink Mfg Co Ltd リポソーム破壊物質の検出方法
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes

Also Published As

Publication number Publication date
DE69623755D1 (de) 2002-10-24
EP0810880A1 (en) 1997-12-10
CN1188704C (zh) 2005-02-09
JPH11500136A (ja) 1999-01-06
KR19980702499A (ko) 1998-07-15
EP0810880B1 (en) 2002-09-18
WO1996025952A1 (en) 1996-08-29
ES2182962T3 (es) 2003-03-16
US6974699B2 (en) 2005-12-13
CN1182372A (zh) 1998-05-20
AU4725996A (en) 1996-09-11
DE69623755T2 (de) 2003-06-05
ZA961427B (en) 1996-08-07
DK0810880T3 (da) 2003-01-06
US20020035084A1 (en) 2002-03-21
GB9503486D0 (en) 1995-04-12
ATE224204T1 (de) 2002-10-15
AU714396B2 (en) 2000-01-06
CA2213566A1 (en) 1996-08-29
US6472365B1 (en) 2002-10-29

Similar Documents

Publication Publication Date Title
Negri et al. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170-and 180-kDa isozymes
Ploug et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
Bade et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
De Pinto et al. Voltage-dependent anion-selective channel (VDAC) in the plasma membrane
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
BR9713521A (pt)
Authier et al. Proteolysis of Glucagon within Hepatic Endosomes by Membrane-associated Cathepsins B and D (∗)
BR9508151A (pt) Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado
Mary et al. Posttranslational Modifications in the C-terminal Tail of Axonemal Tubulin from Sea Urchin Sperm (∗)
Rascón et al. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle
Lawrence et al. Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DE60044420D1 (de) Enzym-Protein-Komplex
Yamamoto et al. Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII
SE0003538D0 (sv) New immunogenic complex
Green et al. Acetylcholine receptors
Križaj et al. Neurotoxic phospholipases A2 ammodytoxin and crotoxin bind to distinct high-affinity protein acceptors in Torpedo marmorata electric organ
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
Terlecky et al. Quantitative analysis of peroxisomal protein import in vitro
PT810880E (pt) Composicoes farmaceuticas e ensaios que utilizam subunidades enzimaticas
Rosenberry et al. Identification and analysis of glycoinositol phospholipid anchors in membrane proteins
ES2092514T3 (es) Conjugados de anticuerpos de dominio variable.
Perron et al. Activation of methotrexate-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro
Raftell et al. Immunochemical studies on a phenobarbital-inducible esterase in rat liver microsomes
NO20003880L (no) Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser